1. Resources and Training
  2. Neuroscience
  3. Product resources and training
  4. Dedicated support

Prescribing information

 

Dedicated support

GILENYACONNECT: the patient support programme which offers patients and healthcare professionals access to nurses and specially developed materials.

GILENYACONNECT is a patient support programme, offering patients and healthcare professionals unique access to a dedicated and experienced nurse support team and a range of specially developed materials to help patients through the first year of their GILENYA journey.

GILENYACONNECT provides UK centres with specialist nurse support for GILENYA pre-initiation, first-dose observation and first-year monitoring.

Diagram of the GILENYACONNECT programme structure. After Gilenya has been prescribed, GILENYACONNECT provides UK centres with specialist nurse support for GILENYA pre-initiation, first-dose observation and first-year monitoring.

 

This flexible programme allows you to choose the components which best suit the needs of your centre.

Since the inception of GILENYA CONNECT, many RRMS patients have benefited from our services:

Infographic of the numbers of patients who have attended first-dose observation, had first-year monitoring, or are at pre-initiation as of the end of December 2018 since the beginning of the service.

*As of the end of December 2018 since the beginning of the service.

GILENYA CONNECT Case Studies

Read opinions and experiences from centres where Gilenya Connect is live below.

 

Survey results from patients enrolled in the GILENYACONNECT programme1

HCPs highlighted that this programme helped MS centres to effectively manage workload and provided a safety net when and where patients required it.1

Infographic of survey results from patients enrolled in the GILENYACONNECT programme. Diagrams showing the %proportion of patients who consider the GILENYACONNECT service provided as excellent, and proportion of patients who would recommend GILENYACONNECT to other patients.

 

The majority of HCPs were totally satisfied with the quality of contact received as part of the GILENYACONNECT service.2

GILENYACONNECT is a healthcare service that is offered as a programme for patients prescribed GILENYA. It is not intended to replace the services of the patient’s NHS medical team.

Gd+: gadolinium enhancing; HCP: healthcare professional; MRI: magnetic resonance imaging; RES: rapidly evolving severe; RRMS: relapsing remitting multiple sclerosis.

Indication: GILENYA is indicated as a single disease modifying therapy in highly active RRMS for the following groups of adult patients and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with ≥1 disease modifying therapy, or patients with RES RRMS defined by ≥2 disabling relapses in 1 year, and with 1 or more Gd+ lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.3

References

  1. Data on File.
  2. Wong O and Ayer M. GilenyaConnect: Patient and healthcare professional satisfaction feedback. Poster.
  3. GILENYA (fingolimod) Summary of Product Characteristics.
Rate this content: 
No votes yet
GIL19-C053d March 2020.
Neuroscience
Article
Print
×

Ask Speakers

×

Medical Information Request

Top Banner. GILENYACONNECT logo.

Pre-initiation check

The first step of GILENYACONNECT, an assessment performed prior to treatment initiation to help you determine your patient’s suitability for GILENYA.Show more

Rate this content: 
No votes yet
GIL19-C053d March 2020.
Neuroscience
Article
Print
Top Banner. GILENYACONNECT logo.

First-dose observation

With GILENYACONNECT, a clinic will perform the required medical observations during the patient’s first dose of GILENYA.Show more

Rate this content: 
No votes yet
GIL19-C053d March 2020.
Neuroscience
Article
Print
Top Banner. GILENYACONNECT logo.

First-year monitoring

Access to nurse support to perform first-year monitoring for patients initiated on GILENYA.Show more

Rate this content: 
No votes yet
GIL19-C053d March 2020.
Neuroscience
Article
Print

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]